Q3 performance guidance is lower than expected and the upper limit of full year profit guidance is reduced. Abbott dropped more than 8%.

Abbott Laboratories fell more than 8% on Thursday, marking the largest drop since June 2021, to $121.08. In terms of news, the financial report showed that Abbott's adjusted earnings per share for the second quarter reached $1.26, slightly higher than the analyst consensus of $1.25. The total revenue for the quarter was $11 billion, exceeding the market's expectation of $10.7 billion.